Your browser is no longer supported. Please, upgrade your browser.
Settings
XTLB XTL Biopharmaceuticals Ltd. daily Stock Chart
XTLB [NASD]
XTL Biopharmaceuticals Ltd.
Index- P/E- EPS (ttm)-0.93 Insider Own1.00% Shs Outstand5.24M Perf Week1.20%
Market Cap17.61M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.14M Perf Month14.29%
Income-2.90M PEG- EPS next Q- Inst Own0.70% Short Float1.53% Perf Quarter28.74%
Sales- P/S- EPS this Y32.40% Inst Trans- Short Ratio5.95 Perf Half Y6.67%
Book/sh1.05 P/B3.20 EPS next Y- ROA-61.30% Target Price30.00 Perf Year-34.76%
Cash/sh- P/C- EPS next 5Y- ROE-83.60% 52W Range1.93 - 6.40 Perf YTD5.89%
Dividend- P/FCF- EPS past 5Y-9.20% ROI- 52W High-47.50% Beta-0.18
Dividend %- Quick Ratio13.60 Sales past 5Y- Gross Margin- 52W Low74.09% ATR0.23
Employees3 Current Ratio13.60 Sales Q/Q- Oper. Margin- RSI (14)59.05 Volatility3.77% 8.70%
OptionableNo Debt/Eq0.00 EPS Q/Q-38.40% Profit Margin- Rel Volume1.16 Prev Close3.30
ShortableYes LT Debt/Eq0.00 EarningsJun 29 Payout- Avg Volume13.20K Price3.36
Recom2.00 SMA201.20% SMA5015.11% SMA2006.32% Volume15,345 Change1.82%
May-08-15Initiated H.C. Wainwright Buy $6
Jul-11-17 07:00AM  Featured Company News Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update Accesswire
Jun-15-17 09:00AM  XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update PR Newswire
Apr-27-17 09:50AM  XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors PR Newswire
Apr-05-17 09:10AM  XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome PR Newswire
09:10AM  XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome
Mar-30-17 08:55AM  XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update PR Newswire +6.30%
Mar-22-17 09:22AM  XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors PR Newswire
Mar-07-17 12:40PM  XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors PR Newswire +6.97%
Mar-01-17 08:30AM  XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement PR Newswire
Feb-17-17 08:00AM  XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering PR Newswire -34.92%
Feb-13-17 09:08AM  XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome PR Newswire -8.23%
Jan-25-17 08:30AM  XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program PR Newswire
Jan-05-17 08:30AM  XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome PR Newswire +11.86%
Dec-19-16 08:00AM  XTL Biopharmaceuticals to Present at Biotech Showcase PR Newswire -19.07%
Dec-06-16 08:30AM  XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update PR Newswire
Nov-09-16 01:25PM  XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements PR Newswire -6.60%
Sep-27-16 08:30AM  XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update PR Newswire
Sep-07-16 08:32AM  XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1 PR Newswire +10.99%
Sep-06-16 08:00AM  XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016 PR Newswire -9.00%
Aug-11-16 09:00AM  XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1 PR Newswire
Jun-02-16 09:11AM  Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected 4 Billion Dollar Market
Jun-01-16 08:30AM  XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update PR Newswire +6.79%
May-16-16 11:45AM  XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016 PR Newswire
Apr-07-16 01:04PM  XTL BIOPHARMACEUTICALS LTD Financials
Mar-31-16 09:45AM  XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update PR Newswire -6.22%
Mar-21-16 08:30AM  XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus PR Newswire
Mar-09-16 08:29AM  Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals PR Newswire
Mar-02-16 09:00AM  XTL Biopharmaceuticals Expands Global IP Portfolio With Issued Patent in Hungary for Lupus Drug hCDR1 PR Newswire
Feb-22-16 09:02AM  XTL Biopharmaceuticals Receives European Medicines Agency's SME Status PR Newswire +5.83%
Feb-10-16 08:30AM  XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes PR Newswire
Jan-27-16 08:30AM  XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America PR Newswire
Jan-25-16 08:30AM  XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for Lupus Drug hCDR1 PR Newswire
Jan-13-16 08:30AM  XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol® PR Newswire
Jan-11-16 08:30AM  XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus PR Newswire -8.39%
Dec-01-15 08:30AM  XTL Biopharmaceuticals Reports Third Quarter 2015 Results and Confirms Intention to Start Lupus Trial In 2016 PR Newswire +7.74%
Nov-09-15 08:30AM  Cellect Biomed Announces Key Leadership Changes GlobeNewswire
Oct-28-15 09:00AM  Dr. Murray Urowitz, of the University of Toronto University Health Network, Provides Overview of an Analysis of Data from a Phase II Clinical Study of hCDR1 (Edratide) for the Treatment of Lupus PR Newswire
Oct-26-15 09:15AM  XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015 PR Newswire +13.66%
Oct-13-15 08:45AM  XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset PR Newswire
Sep-17-15 11:40AM  XTL Biopharmaceuticals Ltd. Earnings Q2, 2015
Sep-03-15 09:00AM  XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC PR Newswire +8.82%
Sep-01-15 09:00AM  XTL Biopharmaceuticals Reports Second Quarter 2015 Results PR Newswire
Aug-26-15 09:00AM  XTL Announces Publication of Results of Phase 2 Study on hCDR1 (Edratide) in Patients with Active Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine PR Newswire
Jun-01-15 08:00AM  XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets PR Newswire
May-11-15 10:50AM  XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference PR Newswire
May-09-15 09:45AM  4 Speculative Biotechs With Huge Analyst Targets at 24/7 Wall St.
May-08-15 09:35AM  XTL Biopharmaceuticals Aims To Tame Lupus, HC Wainwright Initiates At Buy +11.66%
07:43AM  Coverage initiated on XTL Biopharma by H.C. Wainwright
Apr-28-15 07:45AM  XTL Biopharmaceuticals Provides Financial and Operational Update For the Full Year Ended December 31, 2014 PR Newswire
Mar-31-15 09:30AM  XTL Biopharmaceuticals Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire
Feb-17-15 08:30AM  Biotech Investor Alex Rabinovich Increases Stake in XTL Biopharmaceuticals PR Newswire
Dec-30-14 12:23PM  XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors PR Newswire
Dec-08-14 08:30AM  XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets PR Newswire
Dec-01-14 08:00AM  XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014 PR Newswire
Sep-02-14 12:09PM  XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014 PR Newswire
Jul-22-14 02:54PM  XTL Hopes To Begin Major Lupus Trial Next Year at Seeking Alpha
Jul-16-14 09:18AM  XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity PR Newswire
Jun-12-14 08:00AM  XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements PR Newswire
Jun-02-14 09:00AM  XTL Biopharmaceuticals Reports Financial and Operational Results for the First Quarter of 2014 PR Newswire
May-19-14 08:00AM  XTL Biopharmaceuticals Further Strengthens Team for Phase II Lupus Trial with Two Additional Experts PR Newswire
Apr-02-14 04:41PM  XTL Biopharmaceuticals Reports Financial and Operational Results for the Full Year Ended 2013 PR Newswire
Mar-25-14 08:00AM  XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial PR Newswire
Jan-08-14 08:00AM  XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus PR Newswire
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company's lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.